TABLE 2

Basal cGMP formation and stimulation by DEA/NO and HMR-1766

Nondiabetic patientsDiabetic patients
DEA/NO
    Basal (pmol · mg−1 · min−1)12.7 ± 1.9 (17)13.2 ± 1.7 (18)
    Emax (pmol · mg−1 · min−1)475.0 ± 67.2 (16)418.0 ± 58.5 (15)
    Emax (×basal)36.4 ± 2.4 (16)35.9 ± 3.3 (15)
    EC50 (μmol/l)14.1 ± 3.0 (16)8.9 ± 1.2 (15)
    pD2 (−log mol/l)5.0 ± 0.1 (16)5.1 ± 0.1 (15)
HMR-1766
    Basal (pmol · mg−1 · min−1)*14.4 ± 2.4 (17)15.0 ± 2.1 (18)
    Emax (pmol · mg−1 · min−1)95.4 ± 18.3 (17)83.0 ± 11.1 (17)
    Emax (×basal)6.4 ± 0.4 (17)5.8 ± 0.5 (17)
    EC50 (μmol/l)1.4 ± 0.2 (17)1.3 ± 0.3 (17)
    pD2 (−log mol/l)5.9 ± 0.1 (17)6.0 ± 0.1 (17)
  • Data are means ± SE (n).

  • *

    * In the presence of 2% DMSO, n values for basal activity and parameters of stimulation are different because it was not possible to calculate a concentration-response curve in some preparations.